WuXi AppTec (OTCMKTS:WUXIF – Get Free Report) and IQVIA (NYSE:IQV – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.
Profitability
This table compares WuXi AppTec and IQVIA’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| WuXi AppTec | N/A | N/A | N/A |
| IQVIA | 8.10% | 30.25% | 6.54% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for WuXi AppTec and IQVIA, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| WuXi AppTec | 0 | 0 | 0 | 0 | 0.00 |
| IQVIA | 0 | 3 | 13 | 1 | 2.88 |
Valuation and Earnings
This table compares WuXi AppTec and IQVIA”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| WuXi AppTec | N/A | N/A | N/A | N/A | N/A |
| IQVIA | $16.31 billion | 2.38 | $1.36 billion | $8.06 | 29.30 |
IQVIA has higher revenue and earnings than WuXi AppTec.
Institutional and Insider Ownership
89.6% of IQVIA shares are owned by institutional investors. 1.7% of IQVIA shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
IQVIA beats WuXi AppTec on 10 of the 10 factors compared between the two stocks.
About WuXi AppTec
WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical testing services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
About IQVIA
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
Receive News & Ratings for WuXi AppTec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi AppTec and related companies with MarketBeat.com's FREE daily email newsletter.
